Entrada Therapeutics, INC Form 4 insider transactions

Mpm Bioventures 2018, L.P. and 2 others reported changes in beneficial ownership of Entrada Therapeutics, Inc. common stock on September 4, 2026.

MPM BioVentures 2014, L.P. and 9 others reported changes in beneficial ownership of Entrada Therapeutics, Inc. common stock on September 4, 2026.

Mpm Bioventures 2018, L.P. and 2 others reported changes in beneficial ownership of Entrada Therapeutics, Inc. common stock on September 1, 2026.

MPM BioVentures 2014, L.P. and 9 others reported changes in beneficial ownership of Entrada Therapeutics, Inc. common stock on September 1, 2026.

Mpm Bioventures 2018, L.P. and 2 others reported changes in beneficial ownership of Entrada Therapeutics, Inc. common stock on August 27, 2026.

MPM BioVentures 2014, L.P. and 9 others reported changes in beneficial ownership of Entrada Therapeutics, Inc. common stock on August 27, 2026.

MPM BioVentures 2014, L.P. and 9 others reported changes in beneficial ownership of Entrada Therapeutics, Inc. common stock on August 24, 2026.

Mpm Bioventures 2018, L.P. and 2 others reported changes in beneficial ownership of Entrada Therapeutics, Inc. common stock on August 24, 2026.

Kush Parmar, a Director of Entrada Therapeutics, Inc., sold 155,255 shares of common stock on August 6, 2026.

5AM Ventures V, L.P. and 5 others reported changes in beneficial ownership of Entrada Therapeutics, Inc. common stock on August 6, 2026.

5AM Ventures V, L.P. and 5 others reported changes in beneficial ownership of Entrada Therapeutics, Inc. common stock on July 30, 2026.

Kush Parmar, a Director and 10% owner of Entrada Therapeutics, Inc., sold 116,474 shares of common stock on July 30, 2026.

Director Kush Parmar was granted 19,000 stock options in Entrada Therapeutics, Inc. as part of standard equity compensation.

Director Peter S. Kim was granted 19,000 stock options in Entrada Therapeutics, Inc. as part of standard equity compensation.

Entrada Therapeutics director Gina Chapman was granted 19,000 stock options as part of standard equity compensation.

Entrada Therapeutics director Maha Radhakrishnan was granted 19,000 stock options as part of standard equity compensation.

Director Mary Thistle was granted 19,000 stock options in Entrada Therapeutics, Inc. as part of standard equity compensation.

Director Bernhardt G. Zeiher was granted 19,000 stock options in Entrada Therapeutics, Inc. as part of a standard equity compensation arrangement.

Director Bernhardt G. Zeiher acquired 5,000 shares of common stock in Entrada Therapeutics, Inc. for approximately $5.86 per share.

President of Research & Development at Entrada Therapeutics, Sethuraman Natarajan, sold 25,907 shares of common stock.

President and COO Nathan J. Dowden exercised options and sold 15,000 shares of Entrada Therapeutics common stock.

Entrada Therapeutics' Chief Financial Officer, Kory James Wentworth, sold 2,500 shares of common stock on April 1, 2026, as part of a pre-arranged trading plan.

Entrada Therapeutics CFO Kory James Wentworth sold 7,988 shares of common stock for a weighted average price of $12.2549 per share.

Entrada Therapeutics CEO Dipal Doshi reported significant equity grants and option awards, alongside tax-related stock sales, as detailed in a recent SEC Form 4 filing.

Entrada Therapeutics CFO Kory Wentworth reported the grant of restricted stock units and stock options, alongside mandatory tax-related stock sales.

Entrada Therapeutics' President & COO, Nathan J. Dowden, received significant RSU and stock option grants while also executing mandatory sell-to-cover transactions for tax obligations.

Entrada Therapeutics' President of Research & Development, Natarajan Sethuraman, received new equity grants and executed non-discretionary stock sales to cover tax obligations.

Entrada Therapeutics' Chief Financial Officer, Kory James Wentworth, sold 8,910 shares of common stock for approximately $9.98 per share, as part of a pre-arranged 10b5-1 trading plan.

Baker Bros. Advisors and its principals acquired additional common stock in Entrada Therapeutics, increasing their indirect beneficial ownership.

Entrada Therapeutics director and 10% owner Kush M. Parmar reported selling 200,000 shares at a weighted average price of $8.80, retaining 4,056,379 shares indirectly via 5AM funds.